Researchers developed a new method to test potential cancer drugs in mice, allowing them to evaluate multiple genetic variants of the same cancer. This approach could accelerate the development of better treatments by increasing the number of tumour models tested with fewer animals.
A genome-wide association study found two genetic variants associated with high blood pressure and kidney toxicity in cancer patients treated with bevacizumab. The variants, rs6770663 and rs339947, can be used to predict which patients are at risk of severe side effects.
Researchers found that angiotensin receptor blockers (ARBs), commonly used for high blood pressure and heart failure, may increase the likelihood of responding to anti-PD(L)1 therapy. Patients taking ARBs showed a statistically significant improvement in objective response rate and complete response rate compared to those not taking them.
Researchers have discovered a combination of MEK and SHP2 inhibitors effective in targeting the mechanism driving cancer growth in malignant peripheral nerve sheath tumours. The treatment has shown promise in both cell culture and mouse models, offering hope for improved treatment outcomes for patients.
A major study of women with ductal carcinoma in situ (DCIS) found that surgery followed by radiotherapy offers better protection against invasive cancer. However, the benefit of radiotherapy decreases over time, suggesting a need for personalized treatment decisions.
Research at the European Breast Cancer Conference highlights a significant difference in survival rates between breast cancers detected during screening and those detected in the interval between screenings. Screen-detected cancers have higher eight-year distant metastasis-free interval rates, even among high-risk tumours.
Researchers used computer analysis of CT scans to identify women at high risk of cardiovascular disease, with those having the highest CAC score showing a 3.7 times greater risk. The study showed that treating breast cancer means finding a balance between tackling tumors and minimizing side effects, including cardiovascular disease.
The NeoALTTO BIG-06 trial found that women who achieved pathological complete response (pCR) after treatment had better long-term survival without cancer recurrence. Patients receiving both lapatinib and trastuzumab in combination also had a higher rate of pCR, resulting in improved overall survival rates.
A study by Spanish researchers found that women with incident, proliferative benign breast disease are at a nearly four-fold increased risk of developing breast cancer compared to those with no BBD. The study analyzed data from over 629,000 women and recommends personalized screening strategies based on individual risk factors.
A new genetic test identifies patients with invasive lobular carcinoma (ILC) at high risk of recurring and progressing. The 70-gene signature test showed that ILC patients whose genetic make-up puts them at high risk may benefit from additional adjuvant therapy.
A new study suggests that the pandemic may lead to an increase in breast cancer deaths, but delaying or increasing capacity can lower this risk. Increasing staff and equipment would be needed for a full catch-up, but a temporary age limit raise or re-starting as normal with final screenings could be effective alternatives.
A recent study shows that most older women with breast cancer can safely undergo surgery, reducing the gap in survival rates between older and younger women. The research found that surgery is generally well-tolerated and offers slightly lower survival rates for those who don't have it.
Researchers found a pattern of gut bacteria, specifically SCFAs, that may influence the effectiveness of chemotherapy in breast cancer patients. These chemicals play a role in the immune system and may help patients mount an immune response against cancer cells.
Researchers found that asymptomatic breast cancer patients with brain metastases had fewer and smaller tumors, received less aggressive treatment, and lived longer than those who developed symptoms. The study suggests that early detection of brain metastases could improve survival rates for these patients.
Researchers have established new guidelines for analyzing patient-reported outcomes (PROs) in cancer clinical trials, aiming to provide more consistent and comparable Quality of Life (QoL) results. The adoption of these standards will ensure that trial results are more reliable and beneficial for patients.
A meta-analysis of 44 clinical trials found that patient-reported outcomes are significantly associated with overall survival, confirming their importance as prognostic factors. This study aims to improve patient care by providing clinicians with valuable insights into cancer patients' needs and concerns.
Researchers found that irradiating chest lymph nodes in patients with early stage breast cancer improved overall survival by 2.4% compared to treating only the breast/thoracic wall. The study involved 4004 patients and showed no increase in non-breast cancer related mortality or serious complications.
A European Organisation for Research and Treatment of Cancer trial found that combining a 'soft' chemotherapy with antiHER2 therapy is highly active and has low toxicity in older patients with HER2 positive metastatic breast cancer. The regimen resulted in a seven-month longer progression-free survival compared to targeted therapy alone.
The new risk management plan aims to prioritize data quality, reduce costs, and decrease attrition rates in imaging biomarker-driven trials. By identifying risks at trial initiation and allocating resources effectively, the framework can help minimize variability and ensure reproducibility of data.
A recent EORTC study identified key health-related quality of life (HRQOL) components to prioritize in caring for older cancer patients. The study found that HRQOL improves with age for social functioning and financial problems, while physical functioning and constipation worsen.
The EORTC trial 26101 found that bevacizumab treatment in progressive glioblastoma patients did not confer a survival advantage despite prolonged progression-free survival. The combination of bevacizumab and lomustine may prolong PFS but does not impact overall survival.
Researchers analyzed data from 6039 Hodgkin's lymphoma survivors, finding a higher risk of cardiovascular disease associated with specific dose levels of radiation and anthracycline exposure.
A 20-year follow-up of the EORTC boost no-boost trial found that young age, high-grade invasive tumor, and ductal carcinoma in situ were associated with increased local recurrence rates. The study showed substantial benefits from academic clinical research, enabling long-term follow-up and analysis.
The EORTC will present on precision medicine, including a discussion of molecular subgroups and randomized trials. The organization will also focus on survivorship care, exploring the importance of long-term follow-up and evidence-based approaches.
The study found that regional node irradiation had a marginal impact on overall survival for patients with stage I, II, or III breast cancer. This was accompanied by improved disease-free and distant-disease-free survival rates, but long-term radiation effects remain unknown.
The trial showed that early FDG-PET-positive patients benefit from intensification of chemotherapy, leading to improved progression-free survival rates. However, omitting involved-node radiotherapy in early PET-negative patients did not demonstrate non-inferiority to the standard treatment in terms of progression-free survival.
Results from the EORTC trial 62072 show pazopanib improves progression-free survival in soft tissue sarcoma patients without affecting their health-related quality of life. The study provides valuable data on treatment outcomes and cost effectiveness for this patient population.
The DATECAN initiative has published guidelines for time-to-event end point definitions in breast cancer trials, aiming to standardize endpoint usage. This guidance helps researchers compare clinical trial results and make informed decisions about treatment efficacy.
The European Organisation for Research and Treatment of Cancer (EORTC) is part of the CANCER-ID consortium, a €22.7 million project exploring blood-based biomarkers for cancer diagnosis and treatment monitoring.
A recent EORTC trial found that adjuvant Ipilimumab significantly improves recurrence-free survival in patients with completely resected stage III melanoma at high risk of disease recurrence. However, the treatment was also associated with a high rate of immune-related adverse events.
The European Organisation for Research and Treatment of Cancer recently published an article discussing the management of locally advanced inoperable breast cancer. The review, led by Dr. Konstantinos Tryfonidis, examines current treatment options and future directions for improving outcomes.
The EORTC PAMM Group discusses the importance of considering individual patient characteristics and tumor genetics in cancer treatment. Pharmacogenetics can help prescribe efficacious treatment and lower toxicity, improving patient outcomes.
The SPECTAcolor platform has successfully implemented across 19 European clinical centers, recruiting over 500 patients and providing high-quality biological materials. Preliminary analysis reveals mutations in key cancer biomarkers, including KRAS, NRAS, BRAF, PI3K, and mismatch repair.
The EORTC10085/TBCRC/BIG/NABCG International Male Breast Cancer Program found significant improvements in survival for men with breast cancer, but not as high as for women. The study revealed distinct biological characteristics of male breast cancer, including lower rates of hormonal therapy and breast-conserving surgery.
Rare cancer patients face scarce clinical evidence due to conventional trial methodologies requiring large patient numbers. The European Organisation for Research and Treatment of Cancer recommends alternative study designs and collaborative networking.
The 1st EORTC Cancer Survivorship Summit has reported improved survival rates for patients with cancer, while also highlighting the need to address late adverse treatment effects. The summit addressed various topics including second malignancies, cardiovascular disease, and psycho-social problems following cancer treatment.
The European Organisation for Research and Treatment of Cancer (EORTC) will showcase its latest cancer research findings at the ESMO 2014 Congress. The conference will feature various sessions, including a joint symposium on clinical trials and posters focused on immunotherapy and gastrointestinal tumors.
Recent EORTC Imaging Group review highlights MRI and PET's potential for early detection of bone metastases and monitoring treatment response. The study emphasizes the need to overcome current limitations, such as those related to imaging techniques' sensitivity and specificity.
The EORTC presents a European solution for effective cancer drug development through collaborative molecular screening platforms. These platforms enable efficient access to new therapeutic agents and adapt clinical research to individual patient needs.
Richard Sylvester, a renowned expert in non-muscle invasive bladder cancer (NMIBC), received the 2014 Platinum Award from European Urology for his excellence in bladder cancer research. He continues to work on prognostic factors and predictive effects of age on NMIBC outcomes.
The EORTC will present nine abstracts at the ASCO 2014 Annual Meeting, highlighting significant findings in bladder cancer, melanoma, and soft tissue sarcoma. The studies show improvements in progression-free survival for patients with muscle-invasive bladder cancer and adjuvant chemotherapy efficacy in melanoma.
A practical risk-management approach has been outlined by the NCI, NCRI and EORTC to integrate biomarkers into cancer clinical trials. The approach aims to promote quality, facilitate data exchange and accelerate research while respecting local approaches and legislation.
The EORTC and SIOG have updated their expert opinion on NSCLC management in elderly patients, highlighting the need for personalized treatment decisions based on life expectancy and biological age. Multidisciplinary geriatric assessments can improve treatment outcomes for this population.
A recent analysis by the RECIST Working Group found that modeling target lesion tumor growth did not improve prediction of overall survival beyond other components of progression. The study also revealed that new lesions and non-target progressive disease were linked with worse overall survival in multivariate models.
A landmark study found pathological complete response after neoadjuvant chemotherapy to be an independent predictor of favorable clinical outcomes in all molecular subtypes of breast cancer. The treatment administered, taxane or non-taxane, was also shown to impact event-free survival.
The EORTC trial 62012 found that adding ifosfamide to doxorubicin improved median progression-free survival, but not overall survival or tumor shrinkage, in advanced soft tissue sarcoma patients. Combination chemotherapy also resulted in more overall responses compared to doxorubicin alone.
Interim results show omitted radiotherapy associated with higher early relapse rates in stage I/II Hodgkin's lymphoma. The study found no significant differences in progression-free survival between standard and experimental treatment arms.
EORTC analysis confirms performance status, tumor grading, and hemoglobin levels as key predictors of long-term outcomes in pazopanib-treated patients. Long-term responders and survivors accounted for 36% and 34% of patients respectively.
A recent EORTC study found that health-related quality of life (HRQOL) assessments provide relevant information in small-cell lung cancer trials, even when treatment efficacy is similar. The study highlights the need for improved HRQOL reporting in randomized clinical trials to optimize their value.
A 10.4-year median follow-up study by EORTC trial 22921 found that adjuvant chemotherapy does not improve survival or disease-free survival for cT3-resectable T4 M0 rectal cancer patients, highlighting the need for new treatment strategies.